Solitary spinal metastasis of Hürthle cell thyroid carcinoma

2010 ◽  
Vol 17 (6) ◽  
pp. 797-801 ◽  
Author(s):  
Daniel M. Sciubba ◽  
Rory J. Petteys ◽  
Steven Kang ◽  
Khoi D. Than ◽  
Ziya L. Gokaslan ◽  
...  
Keyword(s):  
Thyroid Carcinoma ◽  
Spinal Metastasis ◽  
Hürthle Cell

scholarly journals Expression of miRNA and Occurrence of Distant Metastases in Patients with Hürthle Cell Carcinoma

2016 ◽  
Vol 2016 ◽  
pp. 1-6 ◽  
Author(s):  
Rok Petric ◽  
Barbara Gazic ◽  
Katja Goricar ◽  
Vita Dolzan ◽  
Radan Dzodic ◽  
...  
Keyword(s):  
Thyroid Carcinoma ◽  
Metastatic Disease ◽  
Normal Tissue ◽  
Tumor Tissue ◽  
Thyroid Tissue ◽  
Distant Metastases ◽  
Rare Type ◽  
Hürthle Cell ◽  
U6 Snrna ◽  
Ffpe Samples

Background. Hürthle cell thyroid carcinoma (HCTC) is a rare type of thyroid carcinoma. In the present study, we investigated whether the expression of miRNAs of interest is associated with the occurrence of metastases in patients with HCTC.Materials and Methods. In 39 patients with HCTC (22 with nonmetastatic and 17 with regional or distant metastatic disease), the expression levels of six miRNAs (miR-138, miR-183, miR-221, miR-222, miR-768-3p, and miR-885-5p) and U6 snRNA as endogenous control were determined in FFPE samples of primary tumor and normal thyroid tissue using TaqMan miRNA assays.Results. In patients with HCTC, miR-138 and miR-768-3p were downregulated in tumor samples compared to normal tissue (p=0.013andp=0.010, resp.). These two miRNAs were also significantly downregulated in tumor samples of patients with metastatic disease (p=0.030andp=0.048, resp.) but not in patients with nonmetastatic disease (p=0.249andp=0.101, resp.). In patients with nonmetastatic disease, miR-221 and miR-885-5p were slightly, albeit significantly, upregulated in tumorous compared to normal tissue (p=0.042andp=0.027, resp.).Conclusion. Expression of miRNA (miR-183, miR-221, and miR-885-5p) in tumor tissue is associated with the occurrence of distant metastases in patients with HCTC.

scholarly journals MEN1 Mutations in Hürthle Cell (Oncocytic) Thyroid Carcinoma

2015 ◽  
Vol 100 (4) ◽  
pp. E611-E615 ◽  
Author(s):  
Katayoon Kasaian ◽  
Ana-Maria Chindris ◽  
Sam M. Wiseman ◽  
Karen L. Mungall ◽  
Thomas Zeng ◽  
...  
Keyword(s):  
Thyroid Carcinoma ◽  
Sequence Data ◽  
Whole Genome Sequence ◽  
Regulation Of Transcription ◽  
Whole Genome ◽  
Loss Of Function ◽  
Transcription Control ◽  
Thyroid Carcinomas ◽  
Normal Tissues ◽  
Hürthle Cell

Context and Objective: Oncocytic thyroid carcinoma, also known as Hürthle cell thyroid carcinoma, accounts for only a small percentage of all thyroid cancers. However, this malignancy often presents at an advanced stage and poses unique challenges to patients and clinicians. Surgical resection of the tumor accompanied in some cases by radioactive iodine treatment, radiation, and chemotherapy are the established modes of therapy. Knowledge of the perturbed oncogenic pathways can provide better understanding of the mechanism of disease and thus opportunities for more effective clinical management. Design and Patients: Initially, two oncocytic thyroid carcinomas and their matched normal tissues were profiled using whole genome sequencing. Subsequently, 72 oncocytic thyroid carcinomas, one cell line, and five Hürthle cell adenomas were examined by targeted sequencing for the presence of mutations in the multiple endocrine neoplasia I (MEN1) gene. Results: Here we report the identification of MEN1 loss-of-function mutations in 4% of patients diagnosed with oncocytic thyroid carcinoma. Whole genome sequence data also revealed large regions of copy number variation encompassing nearly the entire genomes of these tumors. Conclusion: Menin, a ubiquitously expressed nuclear protein, is a well-characterized tumor suppressor whose loss is the cause of MEN1 syndrome. Menin is involved in several major cellular pathways such as regulation of transcription, control of cell cycle, apoptosis, and DNA damage repair pathways. Mutations of this gene in a subset of Hürthle cell tumors point to a potential role for this protein and its associated pathways in thyroid tumorigenesis.

ESOPHAGEAL METASTASIS OF HURTHLE CELL THYROID CARCINOMA EIGHT YEARS AFTER A SUBTOTAL THYROIDECTOMY THAT MIMICKED ESOPHAGEAL HEMANGIOMA

2005 ◽  
Vol 20 (10) ◽  
pp. 1628-1629 ◽  
Author(s):  
Murat Akyildiz ◽  
Omer Ozutemiz ◽  
Fulya Gunsar ◽  
Sinan Akay ◽  
Ahmet Aydin ◽  
...  
Keyword(s):  
Thyroid Carcinoma ◽  
Subtotal Thyroidectomy ◽  
Hürthle Cell ◽  
Esophageal Metastasis

A Val 677 Activating Mutation of the Thyrotropin Receptor in a Hürthle Cell Thyroid Carcinoma Associated with Thyrotoxicosis

Thyroid ◽  
1999 ◽  
Vol 9 (1) ◽  
pp. 13-17 ◽  
Author(s):  
DIEGO RUSSO ◽  
MARIWIL G. WONG ◽  
GIUSEPPE COSTANTE ◽  
EUSEBIO CHIEFARI ◽  
PATRICK A. TRESELER ◽  
...  
Keyword(s):  
Thyroid Carcinoma ◽  
Thyrotropin Receptor ◽  
Hürthle Cell ◽  
Activating Mutation

scholarly journals Successful Treatment of Hurthle Cell Thyroid Carcinoma with Lung and Liver Metastasis Using Docetaxel and Cisplatin

2012 ◽  
Vol 42 (11) ◽  
pp. 1086-1090 ◽  
Author(s):  
H. Zhang ◽  
L. Zeng ◽  
C. Liang ◽  
H. Qiu ◽  
M. Zhang ◽  
...  
Keyword(s):  
Liver Metastasis ◽  
Thyroid Carcinoma ◽  
Successful Treatment ◽  
Hürthle Cell

scholarly journals Hurthle Cell Carcinoma of the Thyroid: A Case Report of 12 Cases

2020 ◽  
Vol 63 (12) ◽  
pp. 615-619
Author(s):  
Jung Jun Kim ◽  
Ju Yong Kang ◽  
Ik Joon Choi ◽  
Myung-Chul Lee
Keyword(s):  
Thyroid Carcinoma ◽  
Cell Carcinoma ◽  
Differentiated Thyroid Carcinoma ◽  
World Health ◽  
Clinical Behavior ◽  
Hürthle Cell ◽  
Hürthle Cell Carcinoma ◽  
Hurthle Cell Carcinoma ◽  
Report Data ◽  
Health Organization

Hurthle cell carcinoma (HCC) is a relatively rare disease, which comprises about 3% of differentiated thyroid carcinoma. HCC is considered to have more aggressive clinical behavior compared with other differentiated thyroid carcinoma. However, there has been no consensus about clinical behavior and optimal treatment of HCC because of insufficient reports. Moreover, owing to geographical characteristics, HCC is rarer in Korea than in western countries. Based on 2017 World Health Organization classification, HCC is newly classified as an individual group, not as a subtype of follicular thyroid carcinoma. Therefore, we report data of 12 HCC patients who underwent surgery in our center from January 2000 to May 2020 with a review of the literature.

Sign in / Sign up

Export Citation Format

Share Document